- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sun Pharma gets 6 USFDA observations for Mohali facility
New Delhi: Drugmaker, Sun Pharmaceutical Industries Limited, has recently announced that the US Food and Drug Administration (USFDA) has concluded an inspection with 6 observations at the company's Mohali manufacturing facility (Punjab, India).The USFDA conducted an inspection from August 3, 2022 to August 12, 2022."At the conclusion of the inspection, the US FDA issued a Form-483, with...
New Delhi: Drugmaker, Sun Pharmaceutical Industries Limited, has recently announced that the US Food and Drug Administration (USFDA) has concluded an inspection with 6 observations at the company's Mohali manufacturing facility (Punjab, India).
The USFDA conducted an inspection from August 3, 2022 to August 12, 2022.
"At the conclusion of the inspection, the US FDA issued a Form-483, with 6 observations. The Company is preparing the response to the observations, which will be submitted to USFDA within the stipulated timeline," the company stated in its recent BSE filing.
"The Company is committed to address these observations promptly. The Company remains committed to work closely with the USFDA and continues to enhance its compliance on an ongoing basis," the company informed.
Read also: Sun Pharma, Dr Reddy's Labs and 2 others recall products in US
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751